In this report, Argaam highlights the expected results of Aldawaa Medical Services Co. for the fourth quarter of 2024, as well as its key events, sales, earnings, and performance indicators.
The fourth-quarter revenue is forecast to rise by 8.04% year-on-year (YoY) to SAR 1.57 billion.
| Item | Q4 2023 |
Q1 2024 |
Q2 2024 |
Q3 2024 |
Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Sales | 1,458.09 | 1,516.42 | 1,586.27 | 1,626.23 | 1,575.33 |
| Change % | (0.01%) | 7.73% | 10.41% | 13.02% | 8.04% |
| Item | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 (Average Estimate) |
|---|---|---|---|---|---|
| Net Income | 92.35 | 95.33 | 95.88 | 75.09 | 86.13 |
| Extraordinary income/expense | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Net Profit Before Unusual Items | 92.35 | 95.33 | 95.88 | 75.09 | - |
| EPS Before Unusual Items (Riyal/Share) | 1.09 | 1.12 | 1.13 | 0.88 | 1.01 |
Average Estimates
Aldawaa’s net profit is expected to decline 6.7% to SAR 86.1 million in Q4 2024 from SAR 92.4 million in Q4 2023, according to estimates by four research firms.
| Analyst | Million Riyals |
|---|---|
| SNB Capital Company | 96.10 |
| Osool and Bakheet Investment Co. | 90.40 |
| United Securities Company | 82.00 |
| Riyad Capital | 76.00 |
| Average | 86.13 |
| Net Profit Before Unusual Items (2023 - Q4) | 92.35 |
| Change % | (6.74%) |
Performance and Profitability Indicators
The following table shows the stock performance and P/E ratio as well as the earnings per share trailing 12 months (TTM) and year to date (YTD):
| Item | The Company | TASI |
|---|---|---|
| YTD | (11.10 %) | 2.79 % |
| Change(12M) | (35.70 %) | 3.24 % |
| Previous Close | 78.80 | 12,414.40 |
| P/E adjusted (x) | 18.68 | 24.92 |
| EPS (TTM) before unusual items (SAR/Share) | 4.22 | - |
| P/E (TTM) | 16.52 |
| P/E Before Unusual Items (TTM) | 16.52 |
| P/BV | 4.19 |
| Dividend Yield | 2.36 % |
| Market Cap. (M) | 5,924.50 |
| Return on Average Assets | 7.50 % |
| Return on Average Equity | 12.01 % |
Be the first to comment
Comments Analysis: